Organ-specific response to [177Lu]DOTATATE peptide receptor radionuclide therapy (PRRT) assessed by sequential [68Ga]DOTATOC PET/CT in patients with metastatic small intestine neuroendocrine tumors

  • Published on 01/29/2025
  •  Reading time: 5 min.

Darejan Mamulashvili Bessac 1 , Philippe Baltzinger 2 , Alessio Imperiale 1 ,10  

1 Nuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France
2 Endocrinology, Diabetology, Nutrition, University Hospitals of Strasbourg, Strasbourg University, Strasbourg, France
10 IPHC, UMR 7178, CNRS/Unistra, Strasbourg, France

Abstract

Purpose To evaluate organ-specific response to [177Lu]DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in patients with small intestine neuroendocrine tumor (SiNET) through [68Ga]DOTATOC PET/CT, and to analyze tumor uptake and functional volume variations at different metastatic sites in relation to disease progression during clinical follow-up after treatment.
Methods A retrospective analysis was conducted on 33 metastatic patients....

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Neurology

Receive our newsletter to stay up to date with the latest news in Neurology